Anti-GLDN antibody–associated CIDP (nodopathy): transient IVIg response and B-cell depletion remission
Open Access
- 18 May 2026
- journal article
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Abstract
The classification of chronic inflammatory demyelinating polyneuropathy (CIDP) is evolving with the discovery of autoantibodies against nodal and paranodal proteins, leading to the recognition of "autoimmune nodopathies." While anti-neurofascin-155 (NF155) and anti-contactin-1 (CNTN1) antibodies are well-characterized, the phenotype of anti-gliomedin (GLDN) antibodies remains poorly defined. We present a comprehensive case to delineate its clinical and serological profile. We report a detailed longitudinal case of a patient with anti-GLDN antibody-positive CIDP, including clinical presentation, electrophysiological and imaging studies, serological testing, treatment response, and follow-up. A 48-year-old woman presented with an 11-month history of relapsing-remitting, symmetric sensorimotor polyneuropathy, triggered by immune-activating events. Electrodiagnostic studies confirmed a demyelinating polyneuropathy meeting definitive European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) criteria. Cerebrospinal fluid (CSF) analysis showed marked albuminocytological dissociation (protein 1631 mg/L). Serology was positive for anti-GLDN IgG (cell-based assay titer 1:32). The patient exhibited an excellent but transient response to intravenous immunoglobulin (IVIg), leading to multiple relapses. Subsequent B-cell targeted therapy with rituximab resulted in sustained clinical stabilization, effective B-cell depletion, and negative conversion of anti-GLDN IgG antibody. This case suggests that anti-GLDN antibody-associated CIDP may be associated with a recognizable phenotype within the autoimmune nodopathy spectrum. Potential key features include a relapsing course following immune stimulation, markedly elevated cerebrospinal fluid protein, a unique pattern of robust but unsustained response to intravenous immunoglobulin (IVIg), and a favorable response to B-cell depletion therapy as evidenced by clinical remission and seroconversion.Keywords
Funding Information
- Huashan Hospital Postdoctoral Training Program; the Naval Medical University "Zhuyuan" Talent Program ; and the "Deep Blue Talent" Huashan Backbone Talent Project of the NO.905th Hospital of PLA Navy (No. 2022KYZ09)
This publication has 15 references indexed in Scilit:
- Cerebral‐Cerebellar Cortical Activity and Connectivity Underlying Sensory Trick in Cervical DystoniaAnnals of Clinical and Translational Neurology, 2024
- Microglial activation and blood–brain barrier permeability in cerebral small vessel diseaseBrain, 2021
- Treatment of MOG antibody associated disorders: results of an international surveyJournal of Neurology, 2020
- Cardiovascular factors are related to dopamine integrity and cognition in agingAnnals of Clinical and Translational Neurology, 2019
- Anti–neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivoJournal of Clinical Investigation, 2019
- Contactin 1 IgG4 associates to chronic inflammatory demyelinating polyneuropathy with sensory ataxiaBrain, 2015
- Antibodies to Gliomedin Cause Peripheral Demyelinating Neuropathy and the Dismantling of the Nodes of RanvierThe American Journal of Pathology, 2012
- A novel galectin-1 and interleukin 2 receptor β haplotype is associated with autoimmune myasthenia gravisJournal of Neuroimmunology, 2010
- Group 1 mGluR-Dependent Synaptic Long-Term Depression: Mechanisms and Implications for Circuitry and DiseaseNeuron, 2010
- Gliomedin Mediates Schwann Cell-Axon Interaction and the Molecular Assembly of the Nodes of RanvierNeuron, 2005